Targeted Internal Radiation Therapy in Advanced HCC Patients.

A Randomized Controlled Prospective Study of Targeted Internal Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02724267

Enrollment

200

Registered

2016-03-31

Start date

2012-11-30

Completion date

2015-12-31

Last updated

2016-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Hepatocellular Carcinoma, Internal Radiation

Keywords

131I-chTNT-1/B treatment

Brief summary

The aim of this study is to evaluate the 131I-chTNT-1/B treatment effect and safety of individual therapy using randomized controlled study, in order to acquire the evidence of evidence-based medicine and create a new program of targeted internal radiation therapy in advanced HCC patients.

Interventions

BIOLOGICAL131I-chTNT-1/B

29.6 MBq/kg,intravenous administration in 1 hour，1-3 course of treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

1. Via clinical diagnosis and confirm it is advanced hepatocellular carcinoma 2. mRECIST estimation: necrosis region in HCC 3. Negative iodine allergy test 4. Liver function ：Child-Pugh A/B

Exclusion criteria

1. reject to attend； 2. impossible to come to our hospital for physical examination regularly. 3. Blood clotting function hindrance; 4, Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction,which may affect the treatment of liver cancer.

Design outcomes

Primary

Measure	Time frame
Overall Survival	3 years

Secondary

Measure	Time frame
Time to Progression	3 years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026